MetaStat Stock

MetaStat Financial Debt Ratio

The Financial Debt Ratio of MetaStat (MTST) as of Aug 16, 2026 is 137.06 %. In the previous year, Financial Debt Ratio was 78.39 % — a change of 74.85% (higher).

Financial Debt Ratio

137.06 %

YoY

74.85%

Last updated:

Financial Debt Ratio of MetaStat is 2026 137.06 % . Financial Debt Ratio of MetaStat was 2025 78.39 % . It decreases by 74.85% higher compared to the previous year.
Access this data via the Eulerpool API

MetaStat Stock analysis

What does MetaStat do? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaStat stock

Financial Debt Ratio of MetaStat is 137.06 % in 2026.

Financial Debt Ratio of MetaStat changed from 78.39 % to 137.06 %, representing a 74.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio MetaStat since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's MetaStat with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — MetaStat

All Key Metrics — MetaStat